Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 4/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 7/20 | 0.35 |
| ▸ | KIT | P10721 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21174368 | 0.91 | MET (0.46) | METGRIN2BBTKKITMAPK1 | |
| SCHEMBL21174334 | 0.90 | MET (0.47) | METGRIN2BBTKKITMAPK1 | |
| SCHEMBL21174259 | 0.89 | MET (0.46) | METBTKKITMAPK1PDPK1 | |
| SCHEMBL21174449 | 0.88 | MET (0.45) | METBTKKITMAPK1PDPK1 | |
| SCHEMBL21174178 | 0.87 | MET (0.47) | METBTKKITMAPK1CHRM1 | |
| SCHEMBL21174281 | 0.86 | MET (0.50) | METBTKKITMAPK1PDPK1 | |
| SCHEMBL21174064 | 0.86 | MET (0.49) | METBTKKITMAPK1PDPK1 | |
| SCHEMBL21174231 | 0.86 | MET (0.49) | METBTKKITMAPK1PDPK1 | |
| SCHEMBL30751108 | 0.85 | MET (0.47) | METBTKKITMAPK1 | |
| SCHEMBL27376365 | 0.85 | MET (0.47) | METBTKKITMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3514149-B1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-05-18 | — | — | EP | disclosed |
| EP-3514149-B1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-05-18 | — | — | EP | disclosed |
| US-10774083-B2 | Heterocyclic amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-15 | — | — | US | disclosed |
| US-10774083-B2 | Heterocyclic amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-15 | — | — | US | disclosed |
| US-20190241566-A1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190241566-A1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| EP-3514149-A1 | HETEROCYCLIC AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-07-24 | — | — | EP | disclosed |
| EP-3514149-A1 | HETEROCYCLIC AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241566-A1 | HETEROCYCLIC AMIDE COMPOUND | PRSS8, PRSS1, PRSS2 | MET 4152/4885GRIN2B 2460/4885BTK 3904/4885 |
| US-10774083-B2 | Heterocyclic amide compound | PRSS8, PRSS1, PRSS2 | MET 4152/4885GRIN2B 2460/4885BTK 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.